Bifogade filer
Kurs
+13,04%
Likviditet
0,08 MSEK
Prenumeration
Kalender
Tid* | ||
2026-02-20 | 08:30 | Bokslutskommuniké 2025 |
2025-11-07 | 07:30 | Kvartalsrapport 2025-Q3 |
2025-08-21 | 07:30 | Kvartalsrapport 2025-Q2 |
2025-05-27 | N/A | Årsstämma |
2025-05-16 | 07:30 | Kvartalsrapport 2025-Q1 |
2025-02-20 | 08:30 | Bokslutskommuniké 2024 |
2024-12-23 | - | Split PLUN 40:1 |
2024-12-05 | - | Extra Bolagsstämma 2024 |
2024-11-07 | - | Kvartalsrapport 2024-Q3 |
2024-08-19 | - | Kvartalsrapport 2024-Q2 |
2024-05-31 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2024-05-30 | - | Årsstämma |
2024-05-16 | - | Kvartalsrapport 2024-Q1 |
2024-02-16 | - | Bokslutskommuniké 2023 |
2023-11-07 | - | Kvartalsrapport 2023-Q3 |
2023-10-12 | - | Extra Bolagsstämma 2023 |
2023-07-14 | - | Kvartalsrapport 2023-Q2 |
2023-05-17 | - | Kvartalsrapport 2023-Q1 |
2023-05-05 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2023-05-04 | - | Årsstämma |
2023-02-15 | - | Bokslutskommuniké 2022 |
2022-10-21 | - | Kvartalsrapport 2022-Q3 |
2022-07-14 | - | Kvartalsrapport 2022-Q2 |
2022-05-06 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2022-05-05 | - | Årsstämma |
2022-05-05 | - | Kvartalsrapport 2022-Q1 |
2022-02-18 | - | Bokslutskommuniké 2021 |
2021-10-22 | - | Kvartalsrapport 2021-Q3 |
2021-08-19 | - | Kvartalsrapport 2021-Q2 |
2021-05-12 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2021-05-11 | - | Årsstämma |
2021-05-07 | - | Kvartalsrapport 2021-Q1 |
2021-02-19 | - | Bokslutskommuniké 2020 |
2020-10-23 | - | Kvartalsrapport 2020-Q3 |
2020-08-21 | - | Kvartalsrapport 2020-Q2 |
2020-05-08 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2020-05-07 | - | Årsstämma |
2020-05-07 | - | Kvartalsrapport 2020-Q1 |
2020-02-13 | - | Bokslutskommuniké 2019 |
2019-10-24 | - | Kvartalsrapport 2019-Q3 |
2019-08-21 | - | Kvartalsrapport 2019-Q2 |
2019-05-17 | - | Årsstämma |
2019-05-08 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2019-04-16 | - | Årsstämma |
2019-04-16 | - | Kvartalsrapport 2019-Q1 |
2019-02-22 | - | Bokslutskommuniké 2018 |
2018-11-14 | - | Kvartalsrapport 2018-Q3 |
2018-08-21 | - | Kvartalsrapport 2018-Q2 |
2018-05-17 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2018-05-16 | - | Årsstämma |
2018-05-16 | - | Kvartalsrapport 2018-Q1 |
2018-02-28 | - | Bokslutskommuniké 2017 |
2017-11-16 | - | Kvartalsrapport 2017-Q3 |
2017-08-24 | - | Kvartalsrapport 2017-Q2 |
2017-05-10 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2017-05-09 | - | Årsstämma |
2017-05-09 | - | Kvartalsrapport 2017-Q1 |
2017-02-23 | - | Bokslutskommuniké 2016 |
2016-11-10 | - | Kvartalsrapport 2016-Q3 |
2016-08-25 | - | Kvartalsrapport 2016-Q2 |
2016-05-18 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2016-05-17 | - | Årsstämma |
2016-05-17 | - | Kvartalsrapport 2016-Q1 |
2016-02-26 | - | Bokslutskommuniké 2015 |
2015-11-13 | - | Kvartalsrapport 2015-Q3 |
2015-08-28 | - | Kvartalsrapport 2015-Q2 |
2015-05-12 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2015-05-11 | - | Årsstämma |
2015-05-11 | - | Kvartalsrapport 2015-Q1 |
2015-02-27 | - | Bokslutskommuniké 2014 |
2014-11-28 | - | Kvartalsrapport 2014-Q3 |
2014-08-29 | - | Kvartalsrapport 2014-Q2 |
2014-05-14 | - | Kvartalsrapport 2014-Q1 |
2014-05-06 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2014-05-05 | - | Årsstämma |
2014-02-22 | - | Bokslutskommuniké 2013 |
2013-11-20 | - | Kvartalsrapport 2013-Q3 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
ProstaLund today announces that the company has reached another important milestone with its new platform, CoreTherm® Eagle, for the treatment of benign prostatic enlargement (BPH/BPE). The first ten machines are now manufactured and launching in the first clinics is expected to take place during the end of the year and the first quarter of 2025.
“This is a significant milestone for ProstaLund. The launch of CoreTherm® Eagle gives us great opportunities to open up new treating clinics, both in the Nordics and internationally”, says Anders Kristensson, CEO of ProstaLund.
The new CoreTherm® Eagle is based on the well-proven and established technology, CoreTherm® Concept, which has been developed and refined over 25 years and has been used for over 30,000 treatments of benign prostate enlargement in the Nordic region. CoreTherm® Eagle has been developed to further simplify the treatment process with updates that make it more intuitive and user-friendly.
CoreTherm® is a fast, safe and effective heat treatment for men with benign prostatic hyperplasia (BPH/BPE). The treatment takes less than 15 minutes and requires no surgical intervention. One of the main advantages of CoreTherm® is the ability to treat virtually all different types of patients. Prostate size is not a limiting factor, even prostate glands over 300 ml have been treated. CoreTherm® is performed with local anesthesia, which eliminates the risks of general anesthesia and allows treatment even of patients deemed unsuitable for general or spinal anesthesia.
“With CoreTherm® Eagle, we can give more clinics an opportunity to offer patients an effective outpatient treatment for benign prostate enlargement. Together we can improve the quality of life for men with prostate problems”, says Anders Kristensson.
About CoreTherm®
CoreTherm® is a minimally invasive transurethral microwave thermotherapy for benign prostatic enlargement (BPE). The treatment is performed in an outpatient setting under local anaesthesia and takes less than 15 minutes. No general anaesthesia or spinal block is needed. Follow-up data five years after CoreTherm® treatment shows clinical outcomes comparable to those seen after surgery/TURP (transurethral resection of the prostate), but with lower risk of serious complications. For more information visit, www.coretherm.com.
For further information, please contact:
Anders Kristensson, CEO
Tel. +46 (0) 769 42 12 16
Email: anders.kristensson@prostalund.com
About ProstaLund
ProstaLund AB (publ) is a Swedish medtech company headquartered in Lund that develops and markets innovative products for the treatment of Benign Prostatic Enlargement (BPE). The company has patented the CoreTherm® Concept, a customised thermal treatment for BPE. ProstaLund is listed on Nasdaq First North Growth Market and has approximately 3,600 shareholders. For more information, visit www.prostalund.se. Our press releases are also available to read and download here: www.prostalund.se/pressmeddelanden
Certified Adviser:
Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se